-
An elevated white blood cell count is a risk factor for several cancers in women.
-
Many nursing home patients are admitted with prescriptions for proton pump inhibitors or H2-receptor antagonists without any obvious indication.
-
Incidentalomas:It's All In Your Head, Skin Cancer Screening: Our Patients Want It!, and Bell's Palsy: Steroids, Acyclovir, Both, or Neither?
-
Sorafenib has been approved by the FDA forthe treatment of inoperable hepatocellular cancer. It is an oral multikinase inhibitor that was previously approved for advanced renal cell carcinoma. It is manufactured by Bayer HealthCare AG in Germany and marketed by Bayer Pharmaceuticals Corporation as Nexavar.
-
Although pancreatic cancer growth is considered rapid, early recognition of resectable disease remains the best chance for long-term survival. It is possible that an early sign of evolving pancreatic neoplasm is glucose intolerance. In a series of 30 pancreatic cancer patients evaluated at the Mayo Clinic, CT scans obtained 6 months or more before the diagnosis revealed potentially resectable lesions in some, and this was notably true for those who had CT scans and new-onset diabetes several months before the diagnosis of pancreatic cancer. Thus, physicians evaluating adults with newly diagnosed diabetes should consider the possibility that the glucose intolerance is an accompaniment of early pancreatic neoplasia.
-
IV bisphosphonate treatment is associated with an increased risk of inflammation in the bones of the jaw and face.
-
Neither antibiotics nor nasal steroids nor the combination of the two reduces the duration of acute sinusitis symptoms compared with placebo.
-
A calcium score < 100 eliminates the need for MPS, but patients with a negative MPS often have coronary calcium. These findings imply a potential role for applying CAC screening after MPS among patients manifesting normal MPS.
-
The FDA has approved a combination of 2 antiretrovirals, abacavir and lamivudine for the treatment of HIV-1 infections.
-
Toenail Chromium in Men With Diabetes and Cardiovascular Disease; Combination of Fenofibrate and Rosiglitazone and HDL Cholesterol; Outcomes for Patients with Diet-Controlled Diabetes